Objective: Colorectal carcinoma clinical stage associated proteins would be found by comparing differential expressed proteins from colorectal carcinoma tissues with different clinical stages. Methods: Total protein from colorectal carcinoma tissues were extracted; differential proteome profiles were established and analyzed by means of immobilized pH gradient-based two-dimensional polyacrylamide gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). Results: Well-resolved, reproducible 2-DE profiles of human colorectal carcinoma tissues were obtained. Average protein spots were 970 ± 41, 980 ± 32, 1010 ± 43, 1240 ± 34 in stage I, stage II, stage III, stage IV respectively; Compared to stage I, differential expressed protein spots was 52.00 ± 12 in stage II, 42.00 ± 11 in stage III, 72.00 ± 15 in stage IV; Part of differential expressing proteins were analyzed by mass spectrometry and bioinformation, 19 of them were well characterized. Three proteins were overexpressed in stage I, stage III, stage IV, and one protein were overexpressed in stage IV exclusively. Conclusion: Differential expressed proteins exist in clinical stage of colorectal carcinoma, which would be biomarkers for diagnosis and prediction of prognosis. Objective: Colorectal carcinoma clinical stage associated proteins would be found by comparing differential expressed proteins from colorectal carcinoma tissues with different clinical stages. Methods: Total protein from colorectal carcinoma tissues were extracted; differential proteome profiles were established and analyzed by means of immobilized pH gradient- based two-dimensional polyacrylamide gel electrophoresis (2-DE) and matrix-assisted laser desorption / ionization time of flight mass spectrometry (MALDI-TOF-MS). Results: Well-resolved, reproducible 2-DE profiles of human colorectal carcinoma tissues were The average protein spots were 970 ± 41, 980 ± 32, 1010 ± 43, 1240 ± 34 in stage I, stage II, stage III, stage IV respectively; Compared to stage I, the differential expressed protein spots was 52.00 ± 12 in stage II, 42.00 ± 11 in stage III, 72.00 ± 15 in stage IV; Part of differential expressing proteins were analyzed by mass spectrometry and bioinformation, 19 of them were well characterized. Three proteins were overexpressed in stage I, stage III, stage IV, and one protein were overexpressed in stage IV exclusively. Conclusion: Differential expressed proteins exist in clinical stage of colorectal carcinoma, which would be biomarkers for diagnosis and prediction of prognosis.